Ventas (VTR)
Market Price (2/10/2026): $82.74 | Market Cap: $39.0 BilSector: Real Estate | Industry: Health Care REITs
Ventas (VTR)
Market Price (2/10/2026): $82.74Market Cap: $39.0 BilSector: Real EstateIndustry: Health Care REITs
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18% | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 155x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% | Key risksVTR key risks include [1] significant labor cost pressures and staffing shortages within its senior housing portfolio, Show more. | |
| Attractive yieldDividend Yield is 2.2% | ||
| Low stock price volatilityVol 12M is 22% | ||
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Sustainable & Green Buildings. Themes include Geriatric Care, and ESG REITs. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Attractive yieldDividend Yield is 2.2% |
| Low stock price volatilityVol 12M is 22% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Sustainable & Green Buildings. Themes include Geriatric Care, and ESG REITs. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 155x |
| Key risksVTR key risks include [1] significant labor cost pressures and staffing shortages within its senior housing portfolio, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Ventas (VTR) stock has gained about 15% since 10/31/2025 because of the following key factors:
1. Strong Q4 2025 Earnings and Optimistic 2026 Outlook.
Ventas reported robust financial results for the fourth quarter and full year ended December 31, 2025, significantly exceeding market expectations. Normalized Funds From Operations (FFO) per share increased by 10% year-over-year in Q4 2025 to $0.89, surpassing analyst estimates. The company's revenue also exceeded forecasts, reaching $1.57 billion in Q4. Furthermore, Ventas provided an encouraging outlook for 2026, projecting an 8% year-over-year growth in normalized FFO per share, indicating sustained financial health and growth prospects.
2. Exceptional Performance in Senior Housing Operating Portfolio (SHOP).
A primary driver of Ventas's strong performance was the robust growth within its Senior Housing Operating Portfolio (SHOP). The company achieved over 15% year-over-year same-store cash Net Operating Income (NOI) growth in its SHOP for the full year 2025, marking its fourth consecutive year of double-digit growth in this segment. This strong operational momentum was also reflected in a 300 basis point year-over-year increase in SHOP occupancy during Q4 2025. Management attributed this success to favorable demographic trends, effective operational execution, and limited new supply in the senior housing market.
Show more
1. Strong Q4 2025 Earnings and Optimistic 2026 Outlook.
Ventas reported robust financial results for the fourth quarter and full year ended December 31, 2025, significantly exceeding market expectations. Normalized Funds From Operations (FFO) per share increased by 10% year-over-year in Q4 2025 to $0.89, surpassing analyst estimates. The company's revenue also exceeded forecasts, reaching $1.57 billion in Q4. Furthermore, Ventas provided an encouraging outlook for 2026, projecting an 8% year-over-year growth in normalized FFO per share, indicating sustained financial health and growth prospects.
2. Exceptional Performance in Senior Housing Operating Portfolio (SHOP).
A primary driver of Ventas's strong performance was the robust growth within its Senior Housing Operating Portfolio (SHOP). The company achieved over 15% year-over-year same-store cash Net Operating Income (NOI) growth in its SHOP for the full year 2025, marking its fourth consecutive year of double-digit growth in this segment. This strong operational momentum was also reflected in a 300 basis point year-over-year increase in SHOP occupancy during Q4 2025. Management attributed this success to favorable demographic trends, effective operational execution, and limited new supply in the senior housing market.
Show more
Stock Movement Drivers
Fundamental Drivers
The 12.8% change in VTR stock from 10/31/2025 to 2/9/2026 was primarily driven by a 10.5% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2092026 | Change |
|---|---|---|---|
| Stock Price ($) | 73.34 | 82.75 | 12.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,555 | 5,834 | 5.0% |
| Net Income Margin (%) | 4.3% | 4.3% | 0.6% |
| P/E Multiple | 140.5 | 155.2 | 10.5% |
| Shares Outstanding (Mil) | 456 | 472 | -3.3% |
| Cumulative Contribution | 12.8% |
Market Drivers
10/31/2025 to 2/9/2026| Return | Correlation | |
|---|---|---|
| VTR | 12.8% | |
| Market (SPY) | 1.7% | -12.4% |
| Sector (XLRE) | 3.3% | 31.5% |
Fundamental Drivers
The 24.8% change in VTR stock from 7/31/2025 to 2/9/2026 was primarily driven by a 19.5% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 2092026 | Change |
|---|---|---|---|
| Stock Price ($) | 66.31 | 82.75 | 24.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,302 | 5,834 | 10.0% |
| Net Income Margin (%) | 3.6% | 4.3% | 19.5% |
| P/E Multiple | 156.9 | 155.2 | -1.1% |
| Shares Outstanding (Mil) | 453 | 472 | -4.0% |
| Cumulative Contribution | 24.8% |
Market Drivers
7/31/2025 to 2/9/2026| Return | Correlation | |
|---|---|---|
| VTR | 24.8% | |
| Market (SPY) | 10.1% | -14.8% |
| Sector (XLRE) | 2.8% | 37.3% |
Fundamental Drivers
The 40.8% change in VTR stock from 1/31/2025 to 2/9/2026 was primarily driven by a 31.8% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2092026 | Change |
|---|---|---|---|
| Stock Price ($) | 58.77 | 82.75 | 40.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,802 | 5,834 | 21.5% |
| P/S Multiple | 5.1 | 6.7 | 31.8% |
| Shares Outstanding (Mil) | 415 | 472 | -12.1% |
| Cumulative Contribution | 40.8% |
Market Drivers
1/31/2025 to 2/9/2026| Return | Correlation | |
|---|---|---|
| VTR | 40.8% | |
| Market (SPY) | 16.3% | 21.3% |
| Sector (XLRE) | 4.4% | 51.4% |
Fundamental Drivers
The 76.7% change in VTR stock from 1/31/2023 to 2/9/2026 was primarily driven by a 46.5% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2092026 | Change |
|---|---|---|---|
| Stock Price ($) | 46.84 | 82.75 | 76.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,100 | 5,834 | 42.3% |
| P/S Multiple | 4.6 | 6.7 | 46.5% |
| Shares Outstanding (Mil) | 400 | 472 | -15.3% |
| Cumulative Contribution | 76.7% |
Market Drivers
1/31/2023 to 2/9/2026| Return | Correlation | |
|---|---|---|
| VTR | 76.7% | |
| Market (SPY) | 77.1% | 27.8% |
| Sector (XLRE) | 14.2% | 65.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VTR Return | 8% | -9% | 15% | 22% | 35% | 7% | 100% |
| Peers Return | 14% | -16% | 13% | 19% | 10% | 7% | 50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| VTR Win Rate | 50% | 50% | 58% | 67% | 75% | 100% | |
| Peers Win Rate | 55% | 40% | 58% | 67% | 52% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| VTR Max Drawdown | -6% | -28% | -9% | -16% | -3% | -3% | |
| Peers Max Drawdown | -13% | -25% | -14% | -12% | -15% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WELL, OHI, HR, ARE, NHI. See VTR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/9/2026 (YTD)
How Low Can It Go
| Event | VTR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -43.4% | -25.4% |
| % Gain to Breakeven | 76.6% | 34.1% |
| Time to Breakeven | 696 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -73.1% | -33.9% |
| % Gain to Breakeven | 271.5% | 51.3% |
| Time to Breakeven | 741 days | 148 days |
| 2018 Correction | ||
| % Loss | -34.7% | -19.8% |
| % Gain to Breakeven | 53.2% | 24.7% |
| Time to Breakeven | 479 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -64.2% | -56.8% |
| % Gain to Breakeven | 179.0% | 131.3% |
| Time to Breakeven | 602 days | 1,480 days |
Compare to WELL, OHI, HR, ARE, NHI
In The Past
Ventas's stock fell -43.4% during the 2022 Inflation Shock from a high on 3/29/2022. A -43.4% loss requires a 76.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Ventas (VTR)
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries – healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
AI Analysis | Feedback
Here are 1-3 brief analogies for Ventas (VTR):
- American Tower, but for healthcare properties like hospitals, senior living, and medical offices.
- Prologis for the healthcare industry's real estate.
- Equinix for physical healthcare infrastructure (hospitals, clinics, senior care) instead of digital infrastructure.
AI Analysis | Feedback
- Senior Housing Operating Properties: Ventas owns these properties and partners with third-party managers to operate senior living communities, generating revenue from their financial performance.
- Triple-Net Lease Properties: Ventas leases various healthcare properties (including senior housing, medical office buildings, and life science facilities) to operators under long-term agreements, with tenants responsible for most property expenses.
- Medical Office Buildings: Ventas owns and leases purpose-built facilities for healthcare providers offering outpatient services, often located on hospital campuses or in community settings.
- Research & Innovation Properties: Ventas provides real estate solutions for life science companies and universities, owning facilities designed for research, development, and innovation.
AI Analysis | Feedback
Ventas (NYSE: VTR) is a Real Estate Investment Trust (REIT) that owns and manages healthcare real estate. As such, its primary "customers" are the companies that lease its properties and operate healthcare facilities within them, rather than individuals directly.
Based on their financial filings and investor information, Ventas's major customers (lessees/operating partners) include:
- Brookdale Senior Living Inc. (NYSE: BKD)
- Atria Senior Living
- Sunrise Senior Living
- Ardent Health Services
- LCS
- Holiday Retirement
AI Analysis | Feedback
nullAI Analysis | Feedback
Debra A. Cafaro, Chairman and Chief Executive Officer
Debra A. Cafaro has served as CEO of Ventas, Inc. since 1999 and is recognized as the longest-serving female CEO of an S&P 500 company. Under her leadership, Ventas's equity market capitalization grew significantly from $200 million in 1999 to over $20 billion in less than two decades. Prior to joining Ventas, Cafaro was the President and a Director of an NYSE-listed apartment company, which she was instrumental in selling. She is a lawyer by training and previously served as a U.S. Court of Appeals judicial clerk. Cafaro is also an owner of the MLB Baltimore Orioles, the NHL Pittsburgh Penguins, and the NWSL Chicago Red Stars.
Robert F. Probst, Executive Vice President and Chief Financial Officer
Robert F. Probst has been Ventas's Executive Vice President and Chief Financial Officer since October 2014. Before joining Ventas, he was the Senior Vice President and Chief Financial Officer of Beam Inc., a publicly traded spirits company, from its inception in October 2011 until its sale to Suntory Holdings Limited in May 2014. Probst's previous experience includes serving as Vice President of Finance, Strategy and M&A for the Medication Delivery business division at Baxter International, Inc., and eight years with Diageo PLC, where he was Chief Financial Officer, Global Supply. He began his finance career with roles at The Pillsbury Company and as a Commercial Lending Officer with The Northern Trust Bank.
J. Justin Hutchens, Executive Vice President, Senior Housing and Chief Investment Officer
J. Justin Hutchens has served as Ventas's Executive Vice President, Senior Housing since March 2020 and became Chief Investment Officer in January 2023. He is responsible for Ventas's Senior Housing portfolio and the company's capital allocation strategy. Before Ventas, Hutchens was the Chief Executive Officer for HC-One, which he grew into Britain's largest residential and nursing care home operator. His background includes senior executive and leadership roles in both publicly traded and private equity-backed organizations. He served as President and Chief Investment Officer of HCP (now Healthpeak Properties, Inc.), Chief Executive Officer, Chief Operating Officer, and President of National Health Investors (NYSE: NHI), and Chief Operating Officer of Emeritus Corporation, which was acquired by Brookdale Senior Living, Inc. in 2014.
Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. President and CEO, Lillibridge Healthcare Services, Inc.
Peter J. Bulgarelli holds the titles of Executive Vice President, Outpatient Medical & Research for Ventas, Inc., and President and CEO of Lillibridge Healthcare Services, Inc. Ventas acquired Lillibridge Healthcare Services Inc. in 2010, which has since served as a platform for growth in the medical office buildings market.
Carey S. Roberts, Executive Vice President, General Counsel and Ethics & Compliance Officer
Carey S. Roberts is the Executive Vice President, General Counsel, and Ethics & Compliance Officer for Ventas.
AI Analysis | Feedback
Key Risks to Ventas (VTR) Business:
- Labor Cost Pressures and Staffing Shortages: Ventas faces significant exposure to rising labor costs and staffing shortages, particularly within its Senior Housing Operating Portfolio (SHOP). This can lead to increased wage expenses, pressure on profit margins, challenges in staff retention, and difficulties in maintaining or increasing occupancy rates at its properties.
- High Interest Rates and Substantial Debt Burden: The company carries a considerable amount of debt, which exposes it to the risks associated with a high interest rate environment. Elevated interest rates increase Ventas's borrowing costs, impacting its financial performance and its capacity to acquire or develop new real estate assets. Its leverage is also noted as being higher than some of its peers.
- Tenant Concentration and Operator Performance Risk: In its triple-net-leased property segment, Ventas has a concentration risk, with a significant portion of its net operating income reliant on a limited number of key tenants, such as Brookdale Senior Living, Ardent, and Kindred. Additionally, for its SHOP segment, the company is exposed to the performance of its third-party operators; a failure in execution or persistent labor cost pressures affecting these operators could hinder expected margin expansion.
AI Analysis | Feedback
null
AI Analysis | Feedback
Ventas (symbol: VTR) operates primarily in three major addressable markets within the healthcare real estate sector in the United States: senior housing, medical office buildings, and life science properties.The addressable markets for Ventas's main products and services are as follows:
- Senior Housing: The U.S. senior living market was estimated at USD 907.59 billion in 2024 and is projected to reach USD 1.33 trillion by 2033, demonstrating a compound annual growth rate (CAGR) of 4.42% from 2025 to 2033.
- Medical Office Buildings (MOBs): The U.S. medical office buildings market generated a revenue of USD 14.08 billion in 2023 and is anticipated to reach USD 22.04 billion by 2030.
- Life Science Real Estate: The global life sciences real estate market is forecasted to be USD 3.75 billion in 2025, increasing to USD 4 billion in 2026, and is expected to approach USD 6.76 billion by 2034, with a CAGR of 6.76% over the forecast period of 2025-2034. North America, particularly the U.S., holds a significant share of this market, with North America accounting for 48% of the market share in 2024, and the U.S. alone constituting over 60% of the global footprint in 2023.
AI Analysis | Feedback
Ventas (NYSE: VTR) is expected to drive future revenue growth over the next two to three years through a combination of strong performance in its Senior Housing Operating Portfolio (SHOP), strategic investments in senior housing, and steady contributions from its Outpatient Medical & Research (OMAR) segment, which includes university-based research and innovation centers.
Expected Drivers of Future Revenue Growth:
- Robust Performance in the Senior Housing Operating Portfolio (SHOP): Ventas consistently highlights its SHOP segment as the primary engine for future growth. This is fueled by increasing occupancy rates and strong pricing power (Revenue Per Occupied Room or RevPOR). For example, in Q3 2024, the SHOP same-store portfolio experienced 8.7% revenue growth, driven by a 350 basis point year-over-year increase in average occupancy. Similarly, Q3 2025 saw SHOP same-store cash NOI growth of 16% year-over-year, with revenue increasing 8% due to strength in both occupancy and pricing. The company anticipates continued occupancy growth of approximately 270 basis points in 2025, along with higher RevPOR driven by increasing move-in rents and in-house rates. This growth is supported by the demographic trend of a rapidly expanding 80+ population and historically low new construction in the senior housing market, creating an "unprecedented multiyear growth opportunity".
- Strategic Senior Housing Investments and Acquisitions: Ventas is actively expanding its senior housing footprint through accretive investments and the conversion of triple-net properties to the SHOP model. The company closed or placed under contract $1.7 billion in senior housing investments year-to-date as of Q3 2024, with expectations to generate attractive net operating income (NOI) yields and significant multiyear NOI growth potential. For 2025, Ventas has increased its senior housing investment guidance to $2.5 billion. This strategy involves identifying attractive opportunities and expanding its portfolio with high-performing operators to increase its overall enterprise growth rate.
- Growth in the Outpatient Medical & Research (OMAR) Segment: The OMAR segment, which includes medical office buildings (MOBs) and university-based research & innovation centers, also contributes to revenue growth. In Q3 2025, this segment reported a 3.7% year-over-year cash NOI growth, primarily driven by outpatient medical properties. Occupancy in medical office buildings is reaching new highs, with demand for space substantially outpacing new construction. Ventas has a diversified portfolio in this segment and continues to capitalize on the stable cash flow it provides, along with some growth.
- Expansion of University-Based Research & Innovation (R&I) Portfolio: Ventas's R&I portfolio, often developed in partnership with Wexford Science & Technology, benefits from growing university demand for knowledge communities and strong capital flows into the life science sector. These properties are typically anchored by leading research universities in top life science clusters, such as South San Francisco and Cambridge, and contribute to the company's diversified revenue streams.
AI Analysis | Feedback
Share Repurchases
- Ventas does not currently have a publicly announced share repurchase plan or program in effect.
- Minor share repurchases were observed, including approximately $1.68 million in Q2 2025 and $16.32 million in Q1 2025.
Share Issuance
- Ventas issued 37.3 million shares of common stock in 2024, generating gross proceeds of approximately $2.2 billion.
- In September 2024, the company entered into an "at-the-market" (ATM) Sales Agreement, allowing for the potential sale of up to $2 billion in common stock. This agreement was amended in June 2025, increasing the aggregate gross sales price available for issuance to $2.25 billion.
- Through Q2 2025, Ventas settled 16.4 million shares of common stock under outstanding forward sales agreements for gross proceeds of $1.1 billion, with an additional $0.7 billion of unsettled equity forward sales outstanding.
Outbound Investments
- Ventas completed over $2 billion in investments during 2024, with a primary focus on senior housing.
- Year-to-date in 2025 (as of Q3 2025), the company has closed $2.2 billion in senior housing acquisitions.
- In 2025, Ventas increased its investment volume expectations to $2 billion, up from an earlier estimate of $1.5 billion, with future investments anticipated to be funded mainly through existing unsettled forward equity commitments.
Capital Expenditures
- Ventas's FAD (Funds Available for Distribution) capital expenditures were projected at approximately $285 million at the midpoint for 2025.
- Capital expenditures are primarily focused on routine and non-routine projects that extend the useful life of properties, as well as second-generation leasing commissions and tenant improvements for Outpatient Medical and Research and Triple-Net Leased Properties.
- Over the last two and a half years, Ventas has completed 250 community renovation projects, with an additional 100 planned for completion by the end of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| VTR Stock Falls -5.2% With 7-day Losing Spree On C-Suite Stock Sales | 01/09/2026 | |
| Ventas Earnings Notes | 12/29/2026 | |
| How Low Can Ventas Stock Really Go? | 10/17/2025 | |
| Ventas vs Realty Income: Which Is A Better Investment? | 08/18/2025 | |
| Ventas vs Microsoft: Which Is A Better Investment? | 08/18/2025 | |
| Ventas vs Healthpeak Properties: Which Is A Better Investment? | 08/18/2025 | |
| How Does Ventas Stock Stack Up Against Its Peers? | 08/13/2025 | |
| ARTICLES | ||
| S&P 500 Stocks Trading At 52-Week High | 02/09/2026 | |
| Mid Cap Stocks Trading At 52-Week High | 12/02/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 69.47 |
| Mkt Cap | 11.4 |
| Rev LTM | 2,068 |
| Op Inc LTM | 649 |
| FCF LTM | 940 |
| FCF 3Y Avg | 742 |
| CFO LTM | 1,146 |
| CFO 3Y Avg | 1,057 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 11.5% |
| Rev Chg Q | 11.3% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Mgn LTM | 17.5% |
| Op Mgn 3Y Avg | 18.9% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 43.5% |
| CFO/Rev 3Y Avg | 45.2% |
| FCF/Rev LTM | 38.1% |
| FCF/Rev 3Y Avg | 38.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 11.4 |
| P/S | 8.9 |
| P/EBIT | 18.0 |
| P/E | 25.0 |
| P/CFO | 16.5 |
| Total Yield | 1.8% |
| Dividend Yield | 5.0% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.1% |
| 3M Rtn | 4.3% |
| 6M Rtn | 15.4% |
| 12M Rtn | 30.3% |
| 3Y Rtn | 76.7% |
| 1M Excs Rtn | 5.1% |
| 3M Excs Rtn | 3.3% |
| 6M Excs Rtn | 7.0% |
| 12M Excs Rtn | 14.4% |
| 3Y Excs Rtn | 4.3% |
Segment Financials
Assets by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Senior Housing Operating Portfolio (SHOP) | 12,864 | 12,369 | 12,812 | 10,653 | 10,142 |
| Outpatient Medical and Research Portfolio (OM&R) | 6,943 | 6,558 | 6,342 | 6,710 | 7,173 |
| Triple-net leased properties (NNN) | 4,121 | 4,272 | 4,579 | 5,148 | 6,382 |
| Non-Segment | 797 | 958 | |||
| All other assets | 986 | 1,419 | 995 | ||
| Total | 24,725 | 24,158 | 24,718 | 23,929 | 24,692 |
Price Behavior
Price Behavior
| Market Price | $82.75 | |
| Market Cap ($ Bil) | 37.7 | |
| First Trading Date | 05/05/1997 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $78.08 | $69.84 |
| DMA Trend | up | up |
| Distance from DMA | 6.0% | 18.5% |
| 3M | 1YR | |
| Volatility | 16.1% | 21.6% |
| Downside Capture | -59.66 | -10.90 |
| Upside Capture | -1.79 | 24.96 |
| Correlation (SPY) | -11.2% | 22.1% |
VTR Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.40 | -0.39 | -0.28 | -0.29 | 0.24 | 0.42 |
| Up Beta | -1.33 | -1.24 | -0.69 | -0.16 | 0.32 | 0.33 |
| Down Beta | 0.48 | 0.10 | -0.01 | -0.41 | 0.37 | 0.34 |
| Up Capture | -69% | -58% | -9% | -0% | 14% | 26% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 16 | 30 | 63 | 133 | 396 |
| Down Capture | -116% | -43% | -53% | -70% | -15% | 74% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 23 | 29 | 58 | 112 | 346 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTR | |
|---|---|---|---|---|
| VTR | 40.7% | 21.6% | 1.49 | - |
| Sector ETF (XLRE) | 2.7% | 16.4% | -0.02 | 51.8% |
| Equity (SPY) | 15.5% | 19.4% | 0.62 | 22.0% |
| Gold (GLD) | 78.8% | 24.9% | 2.30 | 11.2% |
| Commodities (DBC) | 9.9% | 16.6% | 0.40 | 7.0% |
| Real Estate (VNQ) | 4.8% | 16.5% | 0.11 | 50.2% |
| Bitcoin (BTCUSD) | -27.0% | 44.8% | -0.57 | -1.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTR | |
|---|---|---|---|---|
| VTR | 15.8% | 25.1% | 0.57 | - |
| Sector ETF (XLRE) | 5.6% | 19.0% | 0.20 | 67.3% |
| Equity (SPY) | 14.2% | 17.0% | 0.67 | 39.3% |
| Gold (GLD) | 22.3% | 16.9% | 1.07 | 16.1% |
| Commodities (DBC) | 11.6% | 18.9% | 0.49 | 13.1% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 68.5% |
| Bitcoin (BTCUSD) | 14.7% | 58.0% | 0.47 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTR | |
|---|---|---|---|---|
| VTR | 8.7% | 34.8% | 0.34 | - |
| Sector ETF (XLRE) | 7.1% | 20.5% | 0.30 | 68.7% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 45.8% |
| Gold (GLD) | 15.8% | 15.5% | 0.85 | 10.5% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 20.4% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 73.1% |
| Bitcoin (BTCUSD) | 69.0% | 66.8% | 1.08 | 13.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/5/2026 | 3.4% | ||
| 10/29/2025 | 6.6% | 7.5% | 15.2% |
| 7/30/2025 | 1.1% | 3.0% | 1.6% |
| 4/30/2025 | -6.5% | -5.7% | -8.3% |
| 2/12/2025 | 8.3% | 11.5% | 11.6% |
| 8/1/2024 | 2.0% | 6.7% | 12.3% |
| 5/1/2024 | 5.5% | 8.3% | 14.7% |
| 2/15/2024 | -3.1% | -3.3% | -6.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 16 | 14 | 13 |
| # Negative | 8 | 9 | 10 |
| Median Positive | 2.5% | 5.3% | 12.3% |
| Median Negative | -3.3% | -4.3% | -7.4% |
| Max Positive | 11.2% | 16.1% | 68.7% |
| Max Negative | -6.8% | -9.7% | -66.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/06/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/10/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cafaro, Debra A | Chairman and CEO | Direct | Sell | 1062026 | 77.26 | 10,322 | 797,475 | 88,516,052 | Form |
| 2 | Probst, Robert F | EVP and CFO | Direct | Sell | 1062026 | 77.25 | 29,930 | 2,312,188 | 10,694,469 | Form |
| 3 | Cafaro, Debra A | Chairman and CEO | Direct | Sell | 12032025 | 80.55 | 10,322 | 831,419 | 92,283,670 | Form |
| 4 | Bulgarelli, Peter J | EVP OM&R-Ventas/Pres&CEO-LHS | Direct | Sell | 11202025 | 80.01 | 2,771 | 221,701 | 8,698,165 | Form |
| 5 | Bulgarelli, Peter J | EVP OM&R-Ventas/Pres&CEO-LHS | Direct | Sell | 11202025 | 80.08 | 2,229 | 178,504 | 8,527,847 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.